Overview

Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if spironolactone, a drug that blocks the action of aldosterone, can make the blood vessels work better in people with obesity. The investigators also want to find out whether spironolactone causes changes in levels of insulin and markers of inflammation.
Phase:
N/A
Details
Lead Sponsor:
Brigham and Women's Hospital
Treatments:
Mineralocorticoids
Spironolactone